💊 药物 A-Z 🧬 靶点 🛠 工具 📚 指南
全部药物 药物分类 治疗领域 不良反应
指南 术语表 时间轴
药物比较 药物旅程 药物家族
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Crisaborole

CHEMBL484785 Phase 4 已批准 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
251.0 g/mol
LogP
—
Phase
4

A nonsteroidal anti-inflammatory ointment used to treat mild to moderate atopic dermatitis (eczema) in adults and children as young as three months. It works by inhibiting phosphodiesterase-4 (PDE4), an enzyme that promotes inflammation in the skin. It provides an alternative to topical corticosteroids without steroid-related side effects.

分子量

251.0500 g/mol

TPSA

62.50 Ų

治疗领域

Psoriasis Atopic Dermatitis Colorectal Cancer

作用机制

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

二维结构

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H10BNO3

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
可旋转键数

                        
2

                    

                    
                    
                    

                        
重原子数

                        
19

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
常见问题

                

                    
                    

                        
                        

                            
A nonsteroidal anti-inflammatory ointment used to treat mild to moderate atopic dermatitis (eczema) in adults and children as young as three months. It works by inhibiting phosphodiesterase-4 (PDE4), an enzyme that promotes inflammation in the skin. It provides an alternative to topical corticosteroids without steroid-related side effects.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This suppresses multiple inflammatory genes encoding cytokines, chemokines, and adhesion molecules while inducing anti-inflammatory proteins.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Crisaborole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL484785.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 44591583.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
医疗免责声明

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.